The Cancer Letter

Inside information on cancer research and drug development

Clinical Roundup

Nab-paclitaxel does not extend biliary tract cancer survival, but may benefit some patients

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Adding nab-paclitaxel to a standard treatment of gemcitabine plus cisplatin does not significantly extend median overall survival time for patients with advanced biliary tract cancers, but it may provide a benefit for subsets of patients with locally-advanced disease or gallbladder adenocarcinoma.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

Ruxolitinib improves CML’s response to standard TKI treatment

Researchers leading the SWOG S1712 clinical trial have found that adding ruxolitinib (Jakafi) to standard tyrosine kinase inhibitor treatment for patients with chronic-phase chronic myeloid leukemia significantly increased the percentage of patients who had a molecular response deep enough to warrant discontinuing treatment. Results were presented at the European School of Haematology’s 26th Annual John...

Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account